On 1 June, member states represented at the World Health Assembly agreed on amendments to the International Health Regulations (2005), alongside the decision to complete negotiations on a pandemic agreement within a year. The pharmaceutical industry shared its response.
Read moreOn 28 May 2024, IFPMA submitted a statement at the World Health Assembly on Provisional Agenda Item 13.3, Working Group on Amendments to the International Health Regulations (2005). IFPMA acknowledges and appreciates the substantial efforts made by Member States in advancing the text of the Working Group on Amendments to the International Health Regulations (WGIHR)....
Read moreOn 28 May 2024, IFPMA, GSCF, GMTA, DVCMN, and BIO submitted a statement to the World Health Assembly on Provisional Agenda Item 13.4, Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement or other international instrument on pandemic prevention, preparedness, and response.
Read moreOn 27 May 2024, IFPMA, IGBA, DITTA, GSCF, WHL, and PATH submitted a constituency statement to the World Health Assembly on Provisional Agenda Item 11.2, NCDs and UHC. IFPMA, IGBA, DITTA, GSCF, WHL, and PATH welcome the agenda item on non-communicable diseases (NCDs) and WHO’s continued commitment to this global health challenge. A life-course approach...
Read moreOn 27 May 2024, IFPMA submitted a statement to the World Health Assembly on Provisional Agenda Item 11.8, Antimicrobial resistance. We are broadly supportive of the three strategic priorities described previously and welcome the newly included elevated strategic priority on effective governance and financing, which also recognizes the important role of all stakeholders, including the...
Read moreOn 27 May 2024, IFPMA submitted a statement to the World Health Assembly on Provisional Agenda Item 15.4, Climate change and health. IFPMA commends the Resolution and the recognition of climate change as an urgent global challenge. Innovative pharmaceutical companies are setting ambitious, science-aligned targets and investing to develop environmentally sustainable products, manufacturing processes, and...
Read moreOn 27 May 2024, IFPMA submitted a statement to the World Health Assembly on Provisional Agenda Item 17, WHO’s 14th General Programme of Work. IFPMA welcomes the strategic focus of the 14th General Programme of Work (GPW14) and appreciates WHO’s efforts to consult with external stakeholders, including the private sector, throughout the drafting process. We...
Read moreOn 21 May, pharmaceutical trade associations at international, European and US-level have welcomed the recognition of the European Medicines Regulatory Network (EMRN) and the United States Food and Drug Administration (FDA) as WHO Listed Authorities, as well as the expanded scope of functions of the Health Sciences Authority (HSA) of Singapore.
Read moreOn 15 May 2024, IFPMA delivered a statement at the UN multistakeholder hearing on antimicrobial resistance, held in New York. The hearing represented an opportunity for all stakeholders to contribute to the ongoing preparatory process for the high-level meeting on AMR, held in September 2024.
Read moreOn 14-15 May 2024, IFPMA was represented at a targeted interdisciplinary discussion within the scope of the WMA Declaration of Helsinki revision. The aim of the meeting was to foster discussion with experts on the paragraphs in the Declaration of Helsinki focused on vulnerable people in research, with a view to contribute the findings to...
Read moreIn a new report, IFPMA reviews the antibiotic pipeline data against bacterial pathogens identified by the WHO and other public health agencies as of the greatest concern, and presents modelling data on the future of the pipeline.
Read more
On 13 May 2024, IFPMA delivered a statement at the WIPO Diplomatic Conference on Genetic Resources and Associated Traditional Knowledge in Geneva, Switzerland. IFPMA and our members support predictable access to genetic resources that can be the starting point for biopharmaceutical research and development. We are concerned that the outcome of this Diplomatic Conference could...
Read more